Drug Trial Radar · NCT02105961
Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD)
Last checked: Nov 20, 2026Latest source record: Aug 16, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
674
Actual
Start
Apr 24, 2014
Primary completion
Jan 16, 2017
Study completion Jan 16, 2017
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Apr 7, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-centered, randomized, placebo-controlled, double-blind, parallel group, trial evaluating 2 doses of mepolizumab against placebo given every 4 weeks through subcutaneous (SC) injection. In severe COPD subjects, sputum eosinophils levels are elevated to similar levels as those seen in severe asthmatics. It is hypothesized that the reduction of eosinophils with mepolizumab in COPD subjects would translate into a reduction of COPD exacerbations. The study will evaluate the efficacy and safety of mepolizumab, in subjects who are at or above the baseline blood eosinophil count of at least 150 cells/microliters who exacerbate despite regular use of maximal tolerated therapy, appropriate for severe COPD subjects, in the 12 months prior to study start. In total, 660 subjects will be randomized in 1:1:1 ratio to receive mepolizumab 300 mg, mepolizumab 100mg, or placebo administered SC. The total duration of subject participation will be approximately 62 weeks, consisting of a 1 to 2 week screening period, 52-week treatment period and 8-week follow-up period.
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
MepolizumabDrug
Humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks, provided as a lyophilised cake in sterile vial. Vial to be reconstituted with Sterile Water for Injection, just prior to use.
PlaceboDrug
Sterile 0.9percent sodium chloride solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Moderate or Severe ExacerbationsTime frame: From randomization to Week 52
Locations
169 sites in 15 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Mobile, Alabama
GSK Investigational Site
Riverside, California
GSK Investigational Site
Upland, California
GSK Investigational Site
Broomfield, Colorado
GSK Investigational Site
Stamford, Connecticut
GSK Investigational Site
Boynton Beach, Florida
GSK Investigational Site
DeLand, Florida
GSK Investigational Site
Edgewater, Florida
GSK Investigational Site
Gainesville, Florida
GSK Investigational Site
Orlando, Florida
GSK Investigational Site
St. Petersburg, Florida
GSK Investigational Site
Adairsville, Georgia
GSK Investigational Site
Duluth, Georgia
GSK Investigational Site
Woodstock, Georgia
GSK Investigational Site
Coeur d'Alene, Idaho
GSK Investigational Site
Bowling Green, Kentucky
GSK Investigational Site
Albuquerque, New Mexico
GSK Investigational Site
Charlotte, North Carolina
GSK Investigational Site
Gastonia, North Carolina
GSK Investigational Site
Huntersville, North Carolina
GSK Investigational Site
Columbus, Ohio
GSK Investigational Site
Portland, Oregon
GSK Investigational Site
Hershey, Pennsylvania
GSK Investigational Site
Oaks, Pennsylvania
GSK Investigational Site
Philadelphia, Pennsylvania
GSK Investigational Site
Charleston, South Carolina
GSK Investigational Site
Easley, South Carolina
GSK Investigational Site
Greenville, South Carolina
GSK Investigational Site
Mt. Pleasant, South Carolina
GSK Investigational Site
Rock Hill, South Carolina
GSK Investigational Site
Fort Worth, Texas
GSK Investigational Site
Richmond, Virginia
GSK Investigational Site
Richmond, Virginia
GSK Investigational Site
Morgantown, West Virginia
GSK Investigational Site
Berazategui, Argentina
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Mendoza, Argentina
GSK Investigational Site
Mendoza, Argentina
Showing 40 of 169 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.